Radiation oncology is a very attractive market indeed. It's a $3 billion-plus capital equipment market predicted to experience a compound annual growth rate of 10 to 15% in the next several years, with the image-guided segment expected to grow at a 35% rate. Approximately 30% of the market is up for grabs over the next three years, as institutions replace old and obsolete equipment. Can small company TomoTherapy sustain the lead it has gained with a new image-guided system that increases the precision of cancer targeting and spares normal tissues, once entrenched multi-billion dollar radiation oncology companies begin to offer aggressive competition?
by Mary Stuart
From the very start, TomoTherapy was not the typical medical device start-up. It’s based in Wisconsin, it operates in a capital equipment segment that has to do with particle physics,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
